Últimas noticias sobre Novartis (NYSE:NVS) Bolsa

Novartis

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ASPN

Los analistas de Wall Street degradaron varias acciones clave. Descubre cuáles y cómo podría impactar en el mercado.

Grandes cambios en calificaciones de acciones: ¿Cómo afectará a tu cartera de inversión?

Novartis AG

NEVADA SUNRISE METALS CRP by NEVADA SUNRISE METALS CORP.

Nevada Sunrise Metals Corp

NOVUS HLDGS LTD SHS by NOVUS HLDGS LTD SHS

Novus Holdings Ltd

Envista Holdings Corporation Common Stock

Envista Holdings Corp

<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a>

Biotech

General

CVAC

MRNA

NVAX

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

<a href="https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html" title="https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html">https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html</a>

Novartis Gets Health Canada Approval For Fabhalta Oral Treatment For Adult Patients With PNH

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Shweta Khajuria downgraded the rating for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from Outperform to In-Line and lowered the price target from $135 to $90. Trade Desk shares closed at $122.23 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Tom Curran downgraded the rating for Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral. Aspen Aerogels shares closed at $11.75 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Charles Neivert downgraded Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Overweight to Neutral and lowered the price target from $41 to $33. Olin shares closed at $27.98 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston downgraded the rating for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral. Novartis shares closed at $107.00 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Buy to Underperform and lowered the price target from $36 to $33. Kraft Heinz shares closed at $28.62 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KHC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png" alt="" class="wp-image-780861" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

UBS analyst Matthew Weston downgrades Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral.

UBS Downgrades Novartis to Neutral

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, <a target="_blank" href="https://www.benzinga.com/quote/NVS" rel="noreferrer noopener">clinical-stage biopharmaceutical company</a>.
Anthos is developing abelacimab, a late-stage medicine to prevent stroke and systemic embolism in patients with atrial fibrillation, a type of irregular heartbeat, or arrhythmia, that occurs when the upper chambers of the heart beat irregularly.
Novartis will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront" rel="noreferrer noopener">pay</a> an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.
The transaction is expected to close in the first half of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43380284/novartis-q4-earnings-beat-estimates-ceo-dismisses-entresto-patent-expiration-worries" rel="noreferrer noopener">Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries</a>
The transaction aligns with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Abelacimab is a fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Phase 2 data showed a significant reduction in bleeding events in patients taking abelacimab versus a standard-of-care direct-oral anticoagulant in patients with atrial fibrillation.
Three Phase 3 trials are ongoing for patients at risk of arterial and venous clots, one in patients with atrial fibrillation and two in cancer-associated thrombosis.
In July 2022 abelacimab received an FDA Fast Track Designation for thrombosis associated with cancer.
In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
In November, Novartis acquired&nbsp;Kate Therapeutics to enhance and strengthen its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42115127/novartis-confident-in-growth-as-it-elevates-midterm-sales-forecast-ceo-narasimhan-highlights-robust-pipeline-supporting-long-term-strategy" rel="noreferrer noopener">portfolio of gene therapies</a>.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Price Action: NVS stock is down 0.31% at $106.52 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43611591/behind-marvell-techs-multi-fold-growth-rd-acquisitions-and-ai-infrastructure" target="_blank" rel="noreferrer noopener">Behind Marvell Tech&#8217;s Multi-Fold Growth: R&amp;D, Acquisitions And AI Infrastructure</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab's potential to provide superior safety
Culminates growth journey as part of Blackstone Life Science

Blackstone-Backed Anthos Therapeutics To Be Acquired By Novartis In $3.1B Deal, Advancing Factor XI Inhibitor Therapy

Super Bowl LIX aired on Sunday, Feb. 9, 2025 and the Philadelphia Eagles defeated the Kansas City Chiefs 40-22, ending the Chiefs' attempt to be the first three-peat <a href="https://www.benzinga.com/general/sports/25/02/43583513/eagles-fly-over-chiefs-40-22-as-super-bowl-lix-tests-potential-137-million-viewership-for-fox">Super Bowl winners.</a>
The game also featured dozens of commercials advertising products and showcasing new movies and television shows. They also featured many celebrity cameos.
What Happened: Super Bowl LIX commercials were <a href="https://www.benzinga.com/general/sports/25/02/43560232/super-bowl-lix-commercials-ai-celebs-muppets-warren-buffett-linked-brand-take-the-spotlight">priced between $7 million and $8 million</a> for a 30-second slot by Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>), which had the media rights to the game.
Fox was able to secure $8 million or more for some last-second advertising inventory ahead of Sunday's game.
This author tracked all the commercials, from the singing of the National Anthem to the final round of ads after the Eagles won the Super Bowl. View the 2024 and 2023 Super Bowl commercials <a href="https://www.benzinga.com/general/sports/24/02/37076429/super-bowl-commercials-2024-complete-list-of-super-bowl-lviii-ads-and-companies-behind-them">here </a>and <a href="https://www.benzinga.com/general/entertainment/23/02/30883140/super-bowl-commercials-2023-the-complete-list-of-super-bowl-lvii-ads-and-the-companies-behi">here</a>. 
The tweet below shows the Super Bowl LIX commercial tracking in real time during the big game.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Super Bowl LIX Commercial Thread. Feel free to retweet. After National Anthem: Misson: Impossible The Final Reckoning Trailer <a href="https://twitter.com/search?q=%24PARA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PARA</a> Sketches <a href="https://twitter.com/search?q=%24SKX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SKX</a> TurboTax <a href="https://twitter.com/search?q=%24INTU&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$INTU</a> NASCAR on Fox <a href="https://twitter.com/search?q=%24FOX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$FOX</a> After Con Toss: Lilo &amp; Stitch Live Action Spot <a href="https://twitter.com/search?q=%24DIS&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DIS</a> YouTubeTV <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a>
&mdash; Chris Katje (@chriskatje) <a href="https://twitter.com/chriskatje/status/1888740049883173010?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here&#8217;s a list of the Super Bowl LIX commercials and the companies behind them.
After National Anthem:
<ul>
<li>"Mission: Impossible – The Final Reckoning" Trailer, Paramount (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDA:PARAA)</li>
<li>Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>)</li>
<li>TurboTax, brand of Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)</li>
<li>NASCAR on Fox</li>
</ul>
After Coin Toss:
<ul>
<li>Lilo &amp; Stitch live action movie teaser for Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</li>
<li>YouTube TV, brand of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
</ul>
After Kickoff, During First Quarter:
<ul>
<li>Dunkin'</li>
<li>"How to Train Your Dragon" live action movie trailer, Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</li>
<li>"Thunderbolts" trailer, Marvel film from Disney</li>
<li>MSC Cruises</li>
<li>Little Caesars</li>
<li>Fox News</li>
<li>T-Mobile (NASDA:TMUS) with Starlink</li>
<li>Homes.com, brand of CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with Ray-Ban</li>
<li>IndyCar racing on Fox</li>
<li>Doritos, brand of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</li>
<li>Cirkul</li>
<li>Michelob Ultra, brand of Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>)</li>
</ul>
After End of First Quarter, During Second Quarter:
<ul>
<li>Disney+ and Hulu streaming platforms</li>
<li>Ritz, brand of Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>)</li>
<li>Red Bull</li>
<li>Squarespace</li>
<li>"The Floor" on Fox</li>
<li>Local Ad</li>
<li>Mountain Dew Baja Blast, brand of PepsiCo</li>
<li>Instacart, brand of Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>)</li>
<li>Coors Light, brand of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</li>
<li>Stand Up to Hate</li>
<li>FanDuel Kick of Destiny challenge, brand of Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>)</li>
<li>"Extracted" on Fox</li>
<li>Uber Eats, brand of Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)</li>
<li>WeatherTech</li>
<li>TurboTax, brand of Intuit</li>
<li>NASCAR on Fox</li>
<li>Google Pixel phone with Gemini AI</li>
<li>UFL on Fox</li>
<li>Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>)</li>
<li>He Gets Us</li>
<li>Liquid Death</li>
<li>HexClad</li>
<li>Duracell, brand of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>OpenAI</li>
<li>CoffeeMate, brand of Nestle (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>)</li>
<li>NFL youth organizations</li>
<li>Ram Truck, brand of Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)</li>
<li>Hellmann's, brand of Unilever (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)</li>
<li>Pringles, brand of Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)</li>
<li>Budweiser, brand of Anheuser-Busch InBev</li>
<li>Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)</li>
<li>NYU Langone Health</li>
<li>Novartis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)</li>
</ul>
After End of Second Quarter, During Halftime, During Third Quarter:
<ul>
<li>IndyCar on Fox</li>
<li>MyFitnessPal</li>
<li>Yahoo!, brand of Apollo Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Verizon Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</li>
<li>Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</li>
<li>Jewel-Osco, brand of Albertsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>)</li>
<li>Bayer Aspirin</li>
<li>"The Masked Singer" on Fox</li>
<li>Fox Nation streaming platform</li>
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>)</li>
<li>Angel Soft, brand of Georgia-Pacific</li>
<li>Reese's Lava Cup, brand of The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>NFL ad</li>
<li>Tubi streaming platform, brand of Fox</li>
<li>Fox shows</li>
<li>Local ad</li>
<li>Local ad</li>
<li>Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)</li>
<li>Meta Platforms</li>
<li>Stand Up to Hate</li>
<li>Nerds</li>
<li>Lay's, brand of PepsiCo</li>
<li>"M3gan 2.0" trailer, distributed by Comcast</li>
<li>Taco Bell, brand of Yum! Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>)</li>
<li>Nerdwallet</li>
<li>Häagen-Dazs</li>
<li>Tubi</li>
<li>Fox Nation</li>
<li>Bud Light, brand of Anheuser-Busch InBev</li>
<li>Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)</li>
<li>Poppi</li>
<li>TV shows on Fox</li>
</ul>
After End of Third Quarter, During Fourth Quarter:
<ul>
<li>Salesforce Inc</li>
<li>Ramp</li>
<li>Tullamore Dew whiskey</li>
<li>Toyota (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)</li>
<li>Sandals Resorts</li>
<li>Local Ad</li>
<li>Jeep, brand of Stellantis</li>
<li>Tubi streaming platform</li>
<li>Fox News</li>
<li>Stella Artois, brand of Anheuser-Busch InBev</li>
<li>Dove, brand of Unilever</li>
<li>Booking.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>)</li>
<li>UFL on Fox</li>
<li>Bosch</li>
<li>Totino's Pizza Rolls, brand of General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>)</li>
<li>GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>)</li>
<li>Fetch</li>
<li>TV shows on Fox</li>
</ul>
End of Game, Eagles win 40-22, Final Ad Spot After Game:
<ul>
<li>Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>)</li>
<li>Adidas (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>)</li>
<li>Cirkul</li>
<li>Vrbo, brand of Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
<li>Universal Resorts</li>
<li>Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</li>
</ul>
The list includes all the Super Bowl LIX commercials that aired from the playing of the national anthem to the first ad break after the Eagles won.
Read Also:<a href="https://www.benzinga.com/general/sports/25/02/43578857/if-you-invested-in-bitcoin-instead-of-buying-super-bowl-tickets-each-year-since-2012-heres-how-much-youd-have-today"> If You Invested in Bitcoin Instead of Buying Super Bowl Tickets Each Year Since 2012, Here&#8217;s How Much You&#8217;d Have Today</a>
Winners and Losers: While everyone will have their own favorites and ads they wish they'd never seen, here's a look at some of the winners and losers.
USA Today asks consumers to <a href="https://admeter.usatoday.com/2025">vote </a>on their favorite Super Bowl commercials each year via the Ad Meter.
Here are the top 10 highest rated ads as of Monday morning:
<ol>
<li>Budweiser – "First Delivery"</li>
<li>Lay's – "The Little Farmer"</li>
<li>Michelob Ultra – "The ULTRA Hustle"</li>
<li>Stella Artois – "David and Dave</li>
<li>NFL – "Somebody"</li>
<li>NFL – "Flag 50"</li>
<li>Bud Light – "Big Men on Cul-De-Sac"</li>
<li>Uber Eats – "Century of Cravings"</li>
<li>Hellmann's – "When Sally Met Hellmann's"</li>
<li>Pfizer – "Knock Out"</li>
</ol>
Here are the 10 lowest rated ads as of Monday morning:
<ol>
<li>Tubi – "The Z Suite"</li>
<li>Fetch – "The Big Reward"</li>
<li>CoffeeMate – "Foam Diva"</li>
<li>Cirkul – "You Got Cirkul"</li>
<li>OpenAI – "ChatGPT: The Intelligence Age"</li>
<li>Squarespace – "A Tale As Old As Websites"</li>
<li>T-Mobile – "A New Era in Connectivity"</li>
<li>DoorDash – "DashPass Math"</li>
<li>Hims &amp; Hers – "Sick of the System"</li>
<li>GoDaddy – "Act Like You Know"</li>
</ol>
The list of winners shows that Anheuser-Busch InBev continues the tradition of unforgettable Super Bowl beer ads once again, taking four places on the top 10 list.
The list of losers shows that companies like CoffeeMate and Hims &amp; Hers, which had their first ever Super Bowl commercials may not have hit the mark with consumers watching.
Read Next: 
<ul>
<li><a href="EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship">EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year&#8217;s NFL Championship</a></li>
</ul>
Photo: Shutterstock

Sports

ADDYY

BKNG

CART

CMCSA

CSGP

DASH

EXPE

FLUT

FOXA

GDDY

GOOG

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INTU

MDLZ

NSRGY

ONON

PARA

PARAA

STLA

TMUS

UBER

Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them

The Kansas City Chiefs are attempting to win a third straight Super Bowl on Sunday with a matchup against the Philadelphia Eagles. While millions of NFL fans will tune in for the big game, millions will also tune in to see the <a href="https://www.benzinga.com/topic/super-bowl">Super Bowl commercials.</a>
What Happened: NFL media partner Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) has the rights to Super Bowl LIX and set its sights on charging $7 million for <a href="https://www.benzinga.com/general/sports/25/01/43324031/super-bowl-lix-commercials-hit-record-8-million-how-fox-corporation-can-win-from-nfl-championship">30-second commercial slots.</a>
The media company was able to secure the majority of its ad slots in the $7 million to $7.5 million range and some last-minute availability came with a price tag of $8 million. Fox also saw strong demand and price increases compared to last year for the pre-game and post-game slots.
While some companies are skeptical to advertise during the Super Bowl due to the high cost, last year's record viewership could lure major brands back, as the game remains one of the most-watched events in the U.S. annually.
Here is a look at the companies that are airing Super Bowl commercials in Super Bowl LIX, as <a href="https://adage.com/article/special-report-super-bowl/super-bowl-2025-commercials-ads-brands-and-agencies/2584221">reported </a>by AdAge.
Read Also: <a href="https://www.benzinga.com/general/sports/24/02/37076429/super-bowl-commercials-2024-complete-list-of-super-bowl-lviii-ads-and-companies-behind-them">Super Bowl Commercials 2024: Complete List Of Super Bowl LVIII Ads And Companies Behind Them</a>
The Public Companies: Here are the companies that are public or tied to a public company that are airing Super Bowl commercials. With strong reception, the ads could have an impact on the company's financials and likewise its stock.
<ul>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): Disney+ streaming ad.</li>
<li>Totino's, brand of General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>): Pizza Rolls makes Super Bowl debut.</li>
<li>GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>): Focus on AI tool Airo with actor Walton Goggins.</li>
<li>Mountain Dew, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): Musician Seal voices a seal.</li>
<li>Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>): Was first company to announce a Super Bowl ad way back in May, Chiefs head coach Andy Reid stars.</li>
<li>Stella Artois, brand of Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>): Brand's fourth Super Bowl ad and first since 2019, David Beckham meets his American twin Dave Beckham (Matt Damon).</li>
<li>Uber Eats, unit of Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): Company's fifth straight year with a Super Bow ad, features Matthew McConaughey, Kevin Bacon, Sean Evans, Martha Stewart, Greta Gerwig and Charli XCX.</li>
<li>Coffee mate, brand of Nestle (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>): Coffee creamer makes Super Bowl debut.</li>
<li>Dove, brand of Unilever (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>): Brand's second straight Super Bowl ad.</li>
<li>Lay's, brand of PepsiCo: Ad for the All-dressed flavor that combines multiple flavors, Lay's first Super Bowl ad in three years.</li>
<li>DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): Focus on DashPass subscriptions with comedian Nate Bargatze.</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): Tech giant returns for first time since 2022 with a focus on its Ray-Ban glasses featuring actors Chris Hemsworth and Chris Pratt.</li>
<li>Pringles, brand of Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>): Eighth consecutive Super Bowl ad from snack brand features actor Adam Brody along with the mustaches of Nick Offerman, James Harden and Andy Reid.</li>
<li>Coors Light, brand of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>): Brand's third straight year with Super Bowl ad, centers on campaign of "Case of the Mondays" for the day after Super Bowl.</li>
<li>Doritos, brand of PepsiCo: Snack brand features a fan-made ad that won a contest.</li>
<li>Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>): Two Super Bowl ads will feature Matthew McConaughey and Woody Harrelson with a focus on AI.</li>
<li>Booking.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>): Travel company back for a fourth straight Super Bowl and features Muppets Miss Piggy, Kermit the Frog and Animal.</li>
<li>Bud Light, brand of Anheuser-Busch InBev: Cul-de-sac party featuring Bud Lights with comedian Shane Gillis, musician Post Malone and NFL great Peyton Manning.</li>
<li>Ram, brand of Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>): Automotive company is back with an ad for its truck with actor Glen Powell.</li>
<li>Reese's, brand of The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>): Focus on the Chocolate Lava Big Cup.</li>
<li>Google, brand of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): No details on the spot.</li>
<li>Instacart, brand of Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>): Delivery company makes Super Bowl debut, features mascots of iconic packaged goods companies.</li>
<li>TurboTax, brand of Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>): Company's 12th consecutive Super Bowl ad, promotes expert-assisted tax filing business.</li>
<li>Hellmann's, brand of Unilever: Likely one of the most talked about ads, Billy Crystal and Meg Ryan reunite at Katz's Delicatessen in New York to create a famous scene from "When Harry Met Sally."</li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>): Super Bowl debut, focus on the company's GLP-1 weight loss treatments.</li>
<li>Michelob Ultra, brand of Anheuser-Busch InBev: Actors William Dafoe and Catherine O'Hara hustle people playing pickleball.</li>
<li>Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>): Pharmaceutical giant makes Super Bowl debut with a 60-second ad on breast cancer.</li>
<li>Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>): Fintech returns to Super Bowl for first time since 2022.</li>
<li>Tubi, brand of Fox Corporation: Streaming platform will be featured in several spots as Fox promotes one of its own products.</li>
<li>Budweiser, brand of Anheuser-Busch InBev: Beer company planned a spot with the famous Clydesdale horses as a regional ad, but bumped up to a national spot after strong reception.</li>
<li>Homes.com, brand of CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>): Real estate company features celebrities in multiple Super Bowl ads.</li>
<li>Taco Bell, brand of Yum! Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>): First Super Bowl ad for restaurant brand in three years, features photos of real customers from drive-thru cameras.</li>
<li>Duracell, brand of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): Battery company makes Super Bowl debut with commercial featuring "The Duracell Scientist" showing people's bad battery decisions.</li>
<li>FanDuel, brand of Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>): Sports betting company features Peyton Manning and Eli Manning in its now annual celebrity field goal kick during the Super Bowl.</li>
<li>Ritz, brand of Mondelez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>): Super Bowl debut.</li>
</ul>
The Private Companies: Here are the private companies that are airing Super Bowl commercials.
<ul>
<li>NerdWallet: Company's first Super Bowl ad, beluga whale mascot voiced by actor Kieran Culkin.</li>
<li>WeatherTech: Company's 13th Super Bowl ad in 12 years, comes after sitting last year's game out.</li>
<li>NFL: The National Football League will have several commercials in the game.</li>
<li>Come Near: "He Gets Us" religious ads as in past Super Bowls.</li>
<li>Little Caesars: First Super Bowl ad since 2020 and comes as the new official pizza of the NFL, Eugene Levy stars.</li>
<li>Nerds: Candy brand is back for a second-straight year with singer Shaboozey.</li>
<li>Squarespace: Former public website building company is back for 11th Super Bowl ad with actor Barry Keoghan.</li>
<li>Foundation to Combat Antisemitism: Patriots owner Robert Kraft is back with his foundation featuring Tom Brady and Snoop Dogg.</li>
<li>Dunkin': Coffee and donut company is back with Ben Affleck.</li>
<li>Häagen-Dazs: Ice cream brand's first ever Super Bowl ad features Vin Diesel, Michelle Rodriguez and Ludacris, all from the "Fast and Furious" franchise.</li>
<li>Poppi: Small soda makes second straight Super Bowl ad appearance with new "Soda Thoughts" campaign.</li>
<li>HexClad: Cookware company makes Super Bowl debut with actor Pete Davidson and celebrity chef Gordon Ramsay, who is a part owner of the company.</li>
<li>Bosch: German company makes Super Bowl debut.</li>
<li>Angel Soft, brand of Georgia-Pacific: Toilet paper brand makes Super Bowl debut.</li>
<li>Liquid Death: Water in a can company makes Super Bowl debut.</li>
<li>Cirkul: Water bottle brand makes Super Bowl debut.</li>
<li>Fetch: Company that rewards shoppers makes Super Bowl debut with a $1.2 million giveaway.</li>
<li>MSC Cruises: European cruise company's Super Bowl debut featuring actors Drew Barrymore and Orlando Bloom.</li>
<li>OpenAI: AI company to make Super Bowl debut, as <a href="https://www.wsj.com/tech/ai/openai-set-to-make-super-bowl-ad-debut-8fa1aff5">reported </a>by the Wall Street Journal Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/02/43542456/14-dot-com-companies-had-super-bowl-commercials-in-2000-heres-how-many-still-exist-today">14 Dot-Com Companies Had Super Bowl Commercials In 2000, Here&#8217;s How Many Still Exist Today</a></li>
</ul>
Photo: kovop/Shutterstock.com

Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight

Novartis CEO Says Co Sets High Bar In Pursuit Of Obesity Deals

U.S. stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. Futures were higher for all four major indices.
The dollar index strengthened after Donald Trump announced Thursday that the U.S. will implement a 25% tariff on imports from Canada and Mexico, effective Saturday, Feb. 1. He also threatened the <a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">BRICS nations</a> to impose 100% tariffs if they issue BRICS reserve currency.
Investors await the Personal Consumption Expenditure data for December, which will be released before the market opens.
The 10-year Treasury yield is currently at 4.53%, and the two-year yield is at 4.21%. The CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.htm">tool </a>indicates an 82% probability that the Federal Open Market Committee will maintain current interest rates in March 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.78%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.45%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.34%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.01%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, both the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were higher. SPY was up 0.42% at $607.59, and QQQ gained 0.80% to reach $527.22, based on <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Stocks rallied Thursday following mixed reactions to a wave of earnings reports and economic data.
This followed Wednesday&#8217;s down session after the Fed held rates steady. Investor sentiment fluctuated due to DeepSeek&#8217;s low-cost AI model launch and Big Tech earnings, this week.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 0.74% despite beating first-quarter revenue and earnings estimates as iPhone sales slipped in Q1 to $69.14 billion, versus $69.7 billion last year. Revenue reached $124.3 billion as compared to $124.13 billion expected by Benzinga Pro, and adjusted earnings per share was $2.40 as compared to the expectation of $2.36 per share.
IBM Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) surged nearly 13% on artificial intelligence growth, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gained 1.6% on strong results, while Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell 6.2% despite exceeding expectations due to weaker cloud revenue.
On the economic front, Q4 GDP growth and jobless claims were slightly below forecasts, but overall economic indicators remain strong, with the Fed, on Wednesday, citing a robust labor market and &#8220;somewhat elevated&#8221; inflation.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.25%</td>
<td>19,681.75</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.53%</td>
<td>6,071.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.38%</td>
<td>44,882.13</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.07%</td>
<td>2,307.45</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the analysts at BlackRock, strong corporate earnings have set the tone for the fourth-quarter season in swing.
&#8220;Even with higher-for-longer interest rates, we think U.S. stocks can keep outperforming this year. We stay overweight. Resilient economic growth is helping sectors beyond tech. That's partly driven by artificial intelligence (AI) spurring earnings beyond the initial winners during an economic transformation and policy change, we think. Yet we eye risks to risk appetite changing this year depending on earnings and policy.&#8221;
With interest rates in focus Ed Yardeni and Eric Wallerstein of Yradeni Research, said in their QuickTakes note that Fed Chair Jerome Powell&#8217;s basic message during his press conference was that the Fed is in no hurry to lower interest rates, but the Fed still intends to lower them over time.
Hence, they described it as a &#8220;dovish pause&#8221;.
Approaching the week from a technical perspective Jeff Buchbinder, the chief equity strategist at LPL Financial said that the S&amp;P 500 remains near record-high territory amid improving market breadth and momentum. &#8220;Technical damage within the heavy-weight tech sector has been minimal as buyers stepped up near support from the mid-January lows.&#8221;
Despite Monday's pullback, sector breadth is also holding up relatively well, with the majority of tech stocks trading above their 200-day moving average, Buchbinder added.
&#8220;However, technical damage has been more pronounced on a relative basis, as the tech sector vs. S&amp;P 500 ratio chart recently dropped to multi-month lows,&#8221; he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>Fed Governor Michelle Bowman will be speaking at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Employment cost index data for Q4 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, the core and headline personal consumption expenditure, along with personal income and spending data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The Chicago Business Barometer (PMI) for January will be out by 9:45 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was up 3.46% in the premarket on Friday after beating the first-quarter expectations on Tuesday, despite a slip in iPhone sales.</li>
</ul>
<ul>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) was up 0.03% as Wall Street expects it to report earnings of 89 cents per share on revenue of $4.99 billion, before the opening bell.</li>
</ul>
<ul>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) fell 0.86% ahead of its earnings to be released before the opening bell. Analysts expect it to report quarterly earnings of 23 cents per share on revenue of $32.24 billion.</li>
</ul>
<ul>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) was down 0.17% as Wall Street expects it to report earnings of $2.11 per share on revenue of $48.41 billion, before the opening bell.</li>
</ul>
<ul>
<li>Other companies that are slated to report earnings today included Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) up 0.6%, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) up 1.49%, Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%, AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) up 0.99%, WW Grainger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) up 1.05% and Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%.</li>
</ul>
<ul>
<li>Nauticus Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) was up 46.15% after announcing a partnership to advance subsea autonomy solutions.</li>
</ul>
<ul>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) was up 19.57% after the company announced a $50 million investment from Softbank.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.08% to hover around $72.67 per barrel.
The gold spot index was down by 0.08% to $2,791.94 per ounce. The Dollar Index was up 0.42% at 108.246 level.
Asian markets were higher on Friday except South Korea's Kospi index. Australia's ASX 200, Japan's Nikkei 225, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex rose. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43376448/elon-musks-x-money-to-see-about-600-million-active-monthly-users-via-visa-direct-integration">Elon Musk&#8217;s &#8216;X Money&#8217; To See About 600 Million Active Monthly Users Via Visa Direct Integration: &#8216;Excited To Partner,&#8217; Says CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Earnings

Equities

Government

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Futures

Forex

Treasuries

ETFs

AAPL

ABBV

CHTR

CIFR

KITT

MSFT

US Stock Futures Climb After Apple Beats Q1 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) shares are trading higher in the <a href="https://www.benzinga.com/premarket" target="_blank" rel="noreferrer noopener">premarket session on Friday.</a>
The Swiss pharma giant <a href="https://www.novartis.com/news/media-releases/novartis-continues-strong-momentum-sales-growth-margin-expansion-reaches-key-innovation-milestones-2024" target="_blank" rel="noreferrer noopener">reported</a> fourth-quarter adjusted earnings per share of $1.98, beating the street view of $1.81. Quarterly sales of $13.153 billion outpaced the analyst consensus estimate of $12.811 billion.
Quarterly net sales grew 16% at constant currency, with volume contributing 15 percentage points to growth.
Heart failure drug Entresto sales grew 34% at constant currency, driven by strong demand and greater market share in the U.S. and Europe for heart failure treatment. It also saw increased use in China and Japan for hypertension management.
In an <a target="_blank" href="https://www.cnbc.com/2025/01/31/novartis-novn-earnings-q4-full-year-fy24.html" rel="noreferrer noopener">interview </a>with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto&#8217;s U.S. patent expiration, which could lead to increased competition from generic drugmakers. He stated that the company has strong replacement power.
Multiple sclerosis drug Kesimpta sales reached $950 million, up 49% at constant currency. Novartis said that sales grew across all regions, reflecting increased demand.
Cosentyx sales in the fourth quarter jumped 24% at constant currency. Sales grew in the U.S., Europe, and emerging growth markets driven by recent launches (including the HS indication and the IV formulation in the U.S.) and volume growth in core indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43350321/abbvie-vs-novartis-which-has-the-technical-edge-before-q4-earnings" rel="noreferrer noopener">AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?</a>
Core operating income was $4.9 billion, up 29% at constant currency, mainly driven by higher net sales. The core operating income margin was 36.9% of net sales, increasing by 3.7 percentage points at constant currency.
&#8220;We also achieved important innovation milestones, including new approvals and readouts for many of the assets that will fuel our growth over the mid- to long-term,&#8221; said Narasimhan in a press release.&nbsp;
Net cash flows from operating activities for Novartis amounted to $4.2 billion in the quarter under review, while free cash flow amounted to $3.6 billion.
The company&#8217;s debt increased to $16.1 billion at December 31, 2024, compared to $10.2 billion net debt in the year-ago period.
Dividend: Novartis declared a dividend of CHF3.50 per share, an increase of 6.1%, proposed for 2024.
FY25 Outlook: &#8220;With the momentum we are seeing in the business, we expect to continue our strong sales growth with margin expansion in 2025 and we remain on track to deliver on our mid-term guidance,&#8221; Narasimhan added.&nbsp;
For FY25, Novartis projects net sales to&nbsp;grow mid-to-high single digits,&nbsp;and core operating income to&nbsp;grow high single to low double digits.
&#8220;We assume&nbsp;Tasigna,&nbsp;Promacta&nbsp;and&nbsp;Entresto&nbsp;US generic entry mid-2025 for forecasting purposes,&#8221; Novartis said in the release.
This apart, the company is focused on executing its pipeline, which includes 15 submission-enabling readouts in the coming years and over 30 assets with the potential to drive long-term growth.
Price Action: NVS shares are trading higher by 1.86% to $106.70 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" target="_blank" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a></li>
</ul>
Photo by Taljat David via Shutterstock.

Guidance

Movers

Media

Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries

<h3>Companies Reporting Before The Bell</h3>
• Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) is estimated to report quarterly earnings at $1.79 per share on revenue of $12.77 billion. 
• Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) is projected to report earnings for its Fiscal Year 2024. 
• Dorian LPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPG#NYSE">LPG</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $89.89 million. 
• Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) is projected to report quarterly earnings at $3.96 per share on revenue of $452.49 million. 
• WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $111.06 million. 
• RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) is estimated to report quarterly earnings at $2.20 per share on revenue of $394.43 million. 
• OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.20 billion. 
• W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) is likely to report quarterly earnings at $9.74 per share on revenue of $4.24 billion. 
• Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) is likely to report quarterly earnings at $7.66 per share on revenue of $214.69 million. 
• Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) is expected to report quarterly earnings at $2.82 per share on revenue of $6.36 billion. 
• Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $13.18 billion. 
• First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $203.83 million. 
• Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) is estimated to report quarterly earnings at $1.35 per share on revenue of $1.57 billion. 
• Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $688.89 million. 
• Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is expected to report quarterly earnings at $1.79 per share on revenue of $88.23 billion. 
• Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) is expected to report quarterly earnings at $1.38 per share on revenue of $730.10 million. 
• Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) is projected to report quarterly earnings at $0.97 per share on revenue of $683.02 million. 
• Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $1.57 billion. 
• Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is estimated to report quarterly earnings at $4.26 per share on revenue of $4.21 billion. 
• Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) is expected to report quarterly earnings at $1.07 per share on revenue of $201.60 million. 
• Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $2.73 billion. 
• Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) is expected to report quarterly earnings at $2.85 per share on revenue of $2.73 billion. 
• LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $9.49 billion. 
• Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is likely to report quarterly earnings at $0.94 per share on revenue of $35.07 billion. 
• Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) is expected to report quarterly earnings at $2.40 per share on revenue of $48.68 billion. 
• Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is estimated to report quarterly earnings at $9.18 per share on revenue of $13.89 billion. 
• Brookfield Business (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBUC#NYSE">BBUC</a>) is likely to report earnings for its fourth quarter. 
• Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) is estimated to report earnings for its fourth quarter. 
• Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEPC#NYSE">BEPC</a>) is likely to report quarterly loss at $0.36 per share on revenue of $2.01 billion. 
• Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) is expected to report quarterly loss at $0.35 per share on revenue of $1.53 billion. 
• ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) is estimated to report quarterly earnings at $1.12 per share on revenue of $1.01 billion. 
• Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $598.58 million. 
• AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is estimated to report quarterly earnings at $2.98 per share on revenue of $14.81 billion. 
• Banco De Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCH#NYSE">BCH</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $804.00 billion. 
• Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) is expected to report quarterly earnings at $1.51 per share on revenue of $2.86 billion. 
• Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $5.05 billion. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCB

BBUC

BEPC

GNTX

Janus Henderson Group plc Ordinary Shares

PIPR

RVTY

VRTS

VSTS

ZAPP

Earnings Scheduled For January 31, 2025

Dividend Proposal&nbsp;
The Novartis Board of Directors proposes a dividend payment of CHF 3.50 per share for 2024, up 6.1% from CHF 3.30 per share in the prior year, representing the 28th consecutive dividend increase since the creation of Novartis in December 1996. Shareholders will vote on this proposal at the AGM on March 7, 2025.

Dividends

Novartis Proposes 6.1% Dividend Increase To CHF 3.50 Per Share For 2024, Pending Shareholder Approval At AGM

2025 outlook Barring unforeseen events; growth vs prior year in cc
&nbsp;Net sales are Expected to grow mid- to high-single-digit&nbsp;
Core operating income is Expected to grow high single to low double-digit

Novartis Expects 2025 Sales Growth Of Mid- To High-Single Digit, And Core Operating Income Increase Of High Single To Low Double-Digit

Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported quarterly earnings of $1.98 per share which beat the analyst consensus estimate of $1.81 by 9.39 percent. This is a 29.41 percent increase over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $13.153 billion which beat the analyst consensus estimate of $12.811 billion by 2.67 percent. This is a 15.14 percent increase over sales of $11.423 billion the same period last year.

Earnings Beats

Novartis Q4 2024 Adj. EPS $1.98 Beats $1.81 Estimate, Sales $13.153B Beat $12.811B Estimate

As AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) prepare to report their <a href="https://www.benzinga.com/earnings">fourth-quarter earnings</a> before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
While AbbVie is stuck in a stagnating trend, Novartis appears to have a stronger bullish momentum. 
Let's break down the charts.
Read Also: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
<h1 class="wp-block-heading">AbbVie: Caught In Neutral Gear</h1>
AbbVie's technical setup presents mixed signals. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png" alt="" class="wp-image-758712" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
AbbVie stock is trading above its short-term moving averages, with the eight-day ($173.14) and 20-day ($175.20) SMAs (simple moving averages) flashing bullish indicators. However, longer-term trends tell a different story — AbbVie stock is aligned closely against its 50-day ($175.33) SMA and below its 200-day ($178.77) SMA, suggesting lingering downside pressure. The MACD (moving average convergence/divergence) indicator at a negative 0.89 reinforces this bearish bias, while the RSI (relative strength index) at 50.39 indicates neutral momentum.
Overall, AbbVie is struggling for direction, with slight selling pressure keeping a lid on any breakout potential. A strong earnings beat could push the stock past key resistance levels, but the current setup suggests AbbVie is vulnerable to further consolidation.
<h1 class="wp-block-heading">Novartis: Riding A Bullish Wave</h1>
Novartis, on the other hand, is trending decisively higher. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png" alt="" class="wp-image-758716" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
Novartis is trading above its short-term and mid-range moving averages, with the eight-day ($101.27), 20-day ($99.57), and 50-day ($100.44) SMAs all acting as support. The MACD at 0.68 points to bullish momentum, while the RSI at 63.61 shows strength without being overbought.
However, the stock remains below its 200-day SMA ($106.77), leaving some room for caution.
<h1 class="wp-block-heading">Investor Implications</h1>
Heading into earnings, Novartis holds the technical advantage, displaying a stronger bullish structure and upward momentum. AbbVie, meanwhile, remains stuck in a range, needing a catalyst to break higher. 
Investors should watch key resistance levels — AbbVie above $177 and Novartis above $106 — for signs of further movement post-earnings.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43244657/goldman-sachs-raises-abbvies-price-forecast-sees-opportunity-despite-challenges">AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive</a></li>
</ul>
Photo: Romix Image via Shutterstock

Technicals

Previews

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Politics

Insurance

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Price Target

Initiation

AMGN

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

SDZNY

TEVA

FDA Adds Boxed Warning About Anaphylaxis With Multiple Sclerosis Medicine Glatiramer Acetate (Copaxone, Glatopa)

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as major tech companies increasingly invest in AI-powered healthcare solutions.
What Happened: Isomorphic Labs, an Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary, is targeting major disease areas including oncology, cardiovascular conditions, and neurodegeneration, founder Demis Hassabis <a href="https://www.ft.com/content/41b51d07-0754-4ffd-a8f9-737e1b1f0c2e">told</a> Financial Times, speaking at the World Economic Forum in Davos. 
The company has already secured partnerships with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) for six drug development programs.
&#8220;It usually takes an average of five to 10 years to discover one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,&#8221; said Hassabis, who recently received the Nobel Prize in Chemistry.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a>
Why It Matters: The announcement comes as Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) unveiled plans for an AI-driven cancer vaccine system capable of delivering personalized treatments within 48 hours. The initiative is <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment">part of a $500 billion AI infrastructure project</a> called Stargate, developed in partnership with OpenAI and SoftBank Group.
Investment in AI-powered drug discovery has gained momentum, with ARK Invest CEO Cathie Wood projecting a $400 billion market opportunity in <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">biologics over the next five years</a>. The sector has attracted significant attention from investors, though companies like Crispr Therapeutics AG and Intellia Therapeutics Inc. have shown considerable market volatility.
Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119243/martin-shkreli-calls-ionq-and-rigetti-best-shorts-despite-recent-stock-gains-cites-offline-quantum-systems">Martin Shkreli Calls IonQ And Rigetti &#8216;Best Shorts&#8217; Despite Recent Stock Gains, Cites Offline Quantum Systems</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

CRSP

NTLA

ORCL

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating on February 6. Richard Vosser's rating i...

Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target ...

Goldman Sachs Keeps Their Hold Rating on Novartis AG (NOVN)

Morgan Stanley analyst Thibault Boutherin initiated coverage of Novartis (NVS) with an Underweight rating and CHF 91 price target The company has a...

Novartis initiated with an Underweight at Morgan Stanley

Moderna ($MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine demand and pipeline unc...

Could Moderna's (MRNA) 65% Stock Plunge Entice a Takeover?

In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of CHF104.00. Ac...

UBS downgrades Novartis AG (NOVN) to a Hold

UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the c...

Novartis downgraded to Neutral from Buy at UBS

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of CHF110...

Novartis AG (NOVN) Gets a Buy from Deutsche Bank

Novartis gets Health Canada approval for Fabhalta oral treatment

Incyte jumps amid takeover speculation

Novartis (NVS)' Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the age...

Novartis' Ianalumab granted FDA orphan designation

INCY

Press Releases

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Contracts

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Comments

Novartis

Noticias

Últimas noticias sobre Novartis (NYSE:NVS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL